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Abstract: Inflammation is a complex response of the body to exogenous and endogenous insults.
Chronic and systemic diseases are attributed to uncontrolled inflammation. Molecules involved
in the initiation of inflammation are very well studied while pathways regulating its resolution
are insufficiently investigated. Approaches to down-modulate mediators relevant for the onset
and duration of inflammation are successful in some chronic diseases, while all of them have
failed in sepsis patients. Inflammation and immune suppression characterize sepsis, indicating
that anti-inflammatory strategies alone are inappropriate for its therapy. Heme oxygenase 1 is a
sensitive marker for oxidative stress and is upregulated in inflammation. Carbon monoxide, which
is produced by this enzyme, initiates multiple anti-inflammatory and pro-resolving activities with
higher production of omega-3 fatty acid-derived lipid metabolites being one of its protective actions.
Pro-resolving lipids named maresins, resolvins and protectins originate from the omega-3 fatty
acids eicosapentaenoic acid and docosahexaenoic acid while lipoxins are derived from arachidonic
acid. These endogenously produced lipids do not simply limit inflammation but actively contribute
to its resolution, and thus provide an opportunity to combat chronic inflammatory diseases and
eventually sepsis.
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1. Introduction
The host response to infection or sterile insults is a complex and tightly regulated process.
First, cytokines, chemokines and prostaglandins are released by the cells residing in the injured
tissues. Endothelial cells and leukocytes upregulate adhesion proteins. These early events initiate
the recruitment of neutrophils to the injured tissue. These cells produce reactive oxygen species,
release antibacterial proteins, and ingest microorganisms and dead cells [1–4]. Neutrophil extracellular
traps, which are composed of DNA, chromatin, antibacterial proteins and enzymes, immobilize and
eventually kill pathogens. The importance of this extracellular pathway in the elimination of microbes
compared to phagocytosis and intracellular killing is unclear. Recent studies suggest that these particles
are abundantly formed in sepsis and contribute to tissue damage [1]. Neutrophils further release
factors which attract monocytes to the inflamed tissues. Monocytes differentiate to macrophages which
phagocytose bacteria and remove dead cells such as apoptotic neutrophils by a special pathway called
efferocytosis [2–4].
Identification of toll-like receptors (TLRs), which recognize pathogen-associated molecular
patterns and damage-associated molecular patterns to initiate nuclear factor kappa B (NF-κB) signaling,
are corner stones in innate immunity research. TLR4 is the receptor for endotoxin specifically
Int. J. Mol. Sci. 2017, 18, 476; doi:10.3390/ijms18030476 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2017, 18, 476 2 of 23
produced by Gram-negative bacteria, TLR2 ligands are peptidoglycans derived from Gram-positive
microorganisms and lipoproteins from Gram-negative bacteria, TLR5 binds to flagellin and TLR9
agonists are viral and bacterial DNA [5]. This list of exogenous TLR agonists is not complete and we
refer to review articles on this topic [6,7].
TLRs also recognize endogenous ligands which are released upon tissue injury and necrotic cell
death. Binding of these molecules initiates an inflammatory response. Several of these agonists have
been identified and are described in detail elsewhere [6,7].
Numerous proteins are regulated in response to infection and/or endotoxaemia. Studies in
endotoxemic mice revealed that modulation of a single protein affects mortality and this has been
proven for more than 100 proteins [8]. This demonstrates the high complexity of the host immune
response which is further complicated by the interplay between different molecules and pathways.
All of the molecules identified in preclinical studies and tested for the treatment of humans, failed
in septic patients [8]. There are nowadays various explanations for these non-satisfactory outcomes.
The heterogeneity among the cohorts is one of them. This topic has been extensively discussed
in recent review articles which also propose several improvements in the design of future clinical
studies [8,9]. One major problem is that sepsis has been looked at as a primarily inflammatory
disease and most approaches were designed to combat inflammation [10]. Animal models used are
mostly designed to study the inflammatory aspects of sepsis. Immune suppression has emerged as a
central pathophysiologic dysfunction in this serious disease and may even occur simultaneously with
inflammation. Agents that potentiate the immune response on the one hand and participate in the
resolution of the pro-inflammatory stage on the other hand may be more appropriate to treat these
patients [10]. Pro-resolving molecules enhance the host immune response and promote the resolution
of inflammation, and are distinct from immunosuppressive agents intended to block the production of
pro-inflammatory mediators or inhibit binding to their respective receptors [11].
In this review article, we focus on the function of the pro-resolving lipids and mostly the lipoxins
and resolvins [12]. Because aspirin contributes to the synthesis of these lipids studies related to
aspirin were included [13]. Carbon monoxide has long been supposed to exert protective effects in
inflammation and has been recently identified to enhance production of pro-resolving lipids [14,15].
The current evidence for beneficial effects of this molecule in sepsis is also summarized. There
is an immense amount of literature on these topics, therefore the review article was limited to the
above-mentioned mediators. Further pro-resolving molecules such as annexin A1 and galectin 1 [16,17]
are not discussed herein. The various studies on glucocorticoid and statin therapy in sepsis are also
not addressed in this review article.
2. Molecules Involved in Resolution of Inflammation
2.1. The Antiinflammatory Cytokine Interleukin (IL)-10
To prevent tissue damage, chronic inflammation and fibrosis, it is essential to timely shut
down pro-inflammatory pathways. Mechanisms of immune response termination are activated early
during initiation of inflammation [12,18]. Blockade of inflammation may also impair the induction
of anti-inflammatory and pro-resolving pathways and delay its termination [12]. A well studied
anti-inflammatory cytokine is interleukin (IL)-10 which binds to IL-10 receptor R1 thereby activating
signal transducer and activator of transcription 3 (STAT3) [18,19]. Macrophages, dendritic cells and
neutrophils respond to IL-10 and altered levels of its receptor during cell maturation and its regulation
by inflammatory and anti-inflammatory mediators are mechanisms to control IL-10 sensitivity [18].
IL-10 contributes to endotoxin tolerance which arises upon secondary exposure to this toxin [20].
One of the underlying mechanisms is the accumulation of the p50 NF-κB subunit and formation of p50
homodimers. These homodimers block binding of the active p65–p50 heterodimer to the respective
promoters [21,22]. Endotoxin tolerance is associated with a switch of inflammatory M1 macrophages
to anti-inflammatory M2-like cells after toxin challenge [23].
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Macrophages deficient in p21 do not develop endotoxin tolerance and binding of the p50–p50
dimer to the promoter regions is impaired. High expression of p21 in monocytes of sepsis patients is
supposed to antagonize hyper-inflammation. These insensitive immune cells do not appropriately
respond to secondary infections and promote sepsis progression [24]. Therefore, IL-10 contributes
to immune suppression in sepsis and propagates secondary infections. In line with this, increased
systemic IL-10 levels correlate with the sepsis score and death in patients [25].
Pro-resolving molecules discussed in the following paragraphs not only enhance
anti-inflammatory effectors, but also boost the host immune response [26] and this may improve
sepsis outcome.
2.2. Carbon Monoxide and Heme Oxygenase
Carbon monoxide is one of the molecules that enhance immune cell function. Carbon monoxide is
produced by the constitutively expressed heme oxygenase (HO)-2, and by HO-1, which is upregulated
upon cellular stress. HO-1 catalyzes the degradation of heme to biliverdin, carbon monoxide and iron
(which binds to ferritin), all exerting anti-oxidative and anti-inflammatory activities [27]. Cluster of
differentiation 163 (CD163) is the macrophage-specific receptor for hemoglobin–haptoglobin uptake
and binding of its ligand enhances IL-10 synthesis which subsequently upregulates HO-1 levels [28,29].
Endogenously formed carbon monoxide acts as a signaling molecule and induces antioxidant
genes [27,30]. Protective effects of carbon monoxide include activation of pathways contributing
to the elimination of microorganisms. Carbon monoxide promotes killing of bacteria and increases
their clearance by macrophages [31]. Engulfment of apoptotic cells by efferocytosis is enhanced [14].
Furthermore, anti-inflammatory cytokines such as IL-10 are induced by carbon monoxide, while
TLR2, -4, -5 and -9 activated pro-inflammatory pathways are repressed in macrophages [32] (Figure 1).
The latter is attributed to blockade of nicotinamide adenosine dinucleotide phosphate (NADPH)
oxidase-mediated production of reactive oxygen species which are involved in TLR translocation to
lipid rafts [32].
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Carbon monoxide lowers the production of inflammatory prostaglandins and thromboxanes. 
Moreover, it enhances the expression of lipoxygenases which are crucial for the synthesis of pro-
resolving lipids from arachidonic acid (lipoxins), eicosapentaenoic acid (EPA) (E-series resolvins) and 
docosahexaenoic acid (DHA) (D-series resolvins, maresins, and protectins) [14]. Resolvins and 
Figure 1. Role of carbon monoxide in the resolution of inflammation. Heme oxygenase 1 in
macrophages is induced in inflammation and carbon monoxide is produced. Carbon monoxide
increases phagocytosis, efferocytosis and synthesis of anti-inflammatory cytokines and pro-resolving
lipids. It suppresses the production of inflammatory lipids and cytokines. IL-10: interleukin-10; LPS:
lipopolysaccharide. ↑, induced; ↓, reduced.
Carbon monoxide lowers the production of inflammatory prostaglandins and thromboxanes.
Moreover, it enhances the expression of lipoxygenases which are crucial for the synthesis of
pro-resolving lipids from arachidonic acid (lipoxins), eicosapentaenoic acid (EPA) (E-series resolvins)
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and docosahexaenoic acid (DHA) (D-series resolvins, maresins, and protectins) [14]. Resolvins and
lipoxin in turn upregulate HO-1 in macrophages [14]. This cooperative cross-talk (Figures 1 and 2) is
highly effective in the resolution of inflammation.
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Figure 2. Crosstalk and positive feedback loop of pro-resolving pathways in macrophages. Carbon
monoxide upregulates heme oxygenase 1 and the production of pro-resolving lipids, which by
themselv s induce heme nase 1. Synthesis of prostaglandins and thromboxanes is reduced
by c onoxide. +, upregulation; −, downregulation.
2.3. Lipid Mediators Derived from Arachidonic Acid
Lipids are involved in the initiation and resolution of inflammation. Pro-inflammatory lipid
species originate mostly from the omega-6 polyunsaturated fatty acid arachidonic acid which is
released from the membrane by the activity of phospholipases. Cyclooxygenases (COX) 1 and 2
catalyze the synthesis of thromboxanes and prostaglandins, collectively termed prostanoids (Figure 3).
Synthe is of prostanoids is stro gly increased in inflamed ti sues where COX2 is induced [33,34].
Prostaglandin E2 is produc i high quantities and xerts mostly pro-inflammatory effects. This lipid
mediator is involved in all processes characteristic for an inflammatory response, namely swelling,
redness and pain [33]. Prostaglandin E2 was shown to induce 15-lipoxygenase (15-LOX) which
catalyzes the production of the pro-resolving lipoxins and thereby contributes to the resolution of an
inflammatory response [35].
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Figure 3. Lipids derived from arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid.
Arachidonic acid is metabolized by cyclooxygenases ( X) 1/2 to prostaglandins and thromboxanes
and by 5-lipoxygenase (5-LOX) to leuk trien s which re involved in the initiation of the inflammatory
respo se (red boxes). Hydroxye cosatetraen ic a ids (HETEs) n lipoxins are also sy thesized from
arachidonic aci and h r 5-, 12- and 15-LOX and cytochrome (Cyt) P450 r involved. Eicosapentaenoic
acid is metabolized to E-series resolvins by Cyt P450 and 5-LOX. Resolvins of the D-series, protectins
and maresins are derived from docosahexaenoic acid. Lipoxins, resolvins, protectins and maresins
(faint green boxes) contribute to the resolution of inflammation.
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Aspirin acetylates COX2 thereby preventing prostaglandin synthesis and enhancing the
production of pro-resolving lipid mediators (Figure 4). Early shutdown of inflammation may
prolong the inflammatory process because of the inappropriate induction of anti-inflammatory and
pro-resolving pathways [36]. Low dose aspirin does, however, not reduce cytokine and prostaglandin
levels while enhancing 15-epi-lipoxin synthesis [37]. Therefore, dosage and timing of therapy may
affect outcome of treatment with aspirin.
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Acetylated COX2 maintains oxygenase activity and converts arachidonic acid to
15(R)-hydroxyeicosatetraenoic acid (HETE), which is a substrate for 5-LOX to form 15-epi-lipoxins
also referred to as aspirin-triggered (AT) lipoxins [38] (Figure 4). Low affinity 15-HETE receptors have
been described which mediate activation of 5-LOX in mast cells [39] indicating that HETE activates
pathways involved in the formation of pro-resolving lipids.
The production of lipoxins can take place in a single cell. Activation of TLR4 in macrophages
results in the accumulation of 15-HETE in the form of membrane phospholipid esters. The activation
of purinergic receptor for extracellular adenosine triphosphate (ATP), P2X7, causes group IVA
cytosolic phospholipase A2 catalyzed hydrolysis of the 15-HETE ester and its conversion to lipoxin by
5-LOX [40].
Intermediate metabolites may also be formed in one cell type and are subsequently transferred to
another type of cell where the final end-product is synthesized. This transcellular process involves
LOX enzymes in leukocytes, epithelial cells and platelets [41,42].
5-LOX is further involved in the synthesis of leukotrienes which exert inflammatory effects
(Figure 3). Leukotriene B4, a dihydroxy derivative of arachidonic acid, initiates and augments
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neutrophil chemotaxis, release of granule products and superoxide anions mostly by binding to
its high affinity receptor BLT1 [43].
Cytochrome P450 enzymes are capable of metabolizing arachidonic acid to epoxyeicosatrienoic
acids and HETEs [27]. Epoxyeicosatrienoic acids induce HO-1 and most of the beneficial activities of
these lipids are blocked by HO-1 inhibition [27]. Biologic functions of these lipids have been nicely
summarized in a recent article [27] and are not further addressed in the present review. It is essential
to note that epoxyeicosatrienoic acid exerts anti-inflammatory activities in murine sepsis while effects
on the host immune system have not been described [44]. Upregulation of HO-1 nevertheless suggests
a role in stimulating immune cell function.
One of the isomers produced by cytochrome P450 is 15(R)-HETE which is converted to
15-epi-lipoxin (Figure 3) [27,34].
In summary, lipids derived from the omega-6 polyunsaturated fatty acid arachidonic acid display
pro- and anti-inflammatory properties (Figure 3). Of note, inflammatory lipids released early during
inflammation induce production of pro-resolving lipids such as lipoxins which down-modulate
inflammatory response and resolve inflammation [35].
2.4. Lipid Mediators Derived from Omega-3 Fatty Acids
Anti-inflammatory and pro-resolving molecules are synthesized from the omega-3 fatty acids
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). E-series resolvins (RvE1 and RvE2) are
derived from EPA by multistep biosynthesis involving cytochrome P450 and 5-LOX. D-series resolvins
(RvD1–RvD6) are generated from DHA by the enzymes 5-LOX and 15-LOX [13,45]. Additional
pro-resolution lipids from DHA are protectins and maresins, and 15-LOX and 12-LOX are involved
in their production, respectively [11,45] (Figure 3). Aspirin-acetylated COX2 produces 18(S)- and
18(R)-hydroxyeicosapentaenoic acid (HEPE) from EPA which are converted to RvE2 enantiomers by
5-LOX and RvE1 enantiomers by 5-LOX and leukotriene A4 hydrolase [46,47] (Figure 4).
Acetylated COX2 further converts DHA to 17(R)-hydroxy-DHA which is oxidized to 17-epi-RvD1
by 5-LOX, also named aspirin-triggered RvD1 (AT-RvD1) [13]. Additional AT-RvD and AT-protectin
D1 pro-resolving lipids have been described and biologic activities for most of them have been
demonstrated [48].
Formation of these pro-resolving lipids usually is a transcellular process involving different cell
types. For instance, synthesis of AT-RvDs starts with hydroxylation of DHA in vascular endothelial
cells which is followed by transfer to nearby neutrophils where these lipids are being oxygenated to
AT-RvDs [49].
2.5. Biologic Activities of Pro-Resolving Lipids
Biologic activities of the pro-resolving lipids are manifold and encompass different cells and
molecules involved in inflammation. These protective functions are overlapping but not completely
identical (Table 1).
Lipoxin A4 blocks transmigration of neutrophils, inhibits their adhesion and their release of
azurophilic granules [50,51] (Figure 5, Table 1). Myeloperoxidase contributes to the production of
cytotoxic oxidants and further protects neutrophils from apoptosis. 15-epi-lipoxin interferes with
myeloperoxidase mediated activation of several kinases and leads to neutrophil apoptosis [52].
RvE1 enhances cell death of neutrophils arousing from the phagocytosis of opsonized
Escherichia coli or yeast, and this effect is mediated by the leukotriene B4 receptor BLT1 [53].
Upregulation of the C-C chemokine receptor 5 (CCR5) on apoptotic polymorphonuclear cells (PMNs)
is supposed to terminate C-C motif chemokine ligand 3 (CCL3) and CCL5 signaling. Lipoxin A4, RvE1
and protectin D1 increase CCR5 levels and thereby terminate chemokine signaling [54].
These specialized lipids further increase monocyte recruitment and enhance macrophage
phagocytosis and efferocytosis [45,55] (Figure 5, Table 1). In macrophages, M2-specific proteins such
as IL-10 are induced and expression of HO-1 is also increased. M2 macrophages are characterized by a
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lower release of pro-inflammatory cytokines and lipids, which is partly attributed to the production of
protectin by these cells [56,57]. RvE1 and 15-epi lipoxin protect macrophages from oxidative stress
associated apoptotic cell death and this contributes to the removal of harmful debris and the resolution
of inflammation [58,59].
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efferocytosis and survival. These lipids also promote the polarization of macrophages to M2 cells and
induce heme oxygenase 1 (HO-1) and synthesis of protectins. Release of inflammatory cytokines is
reduced; +, increase; −, reduction.
I dendritic cells, the production of the inflammatory cytokine IL-12 is enhanced by inflammatory
mediators and this is blocked by lipoxin A4 and RvE1 [60,61]. LPS-induced secretion of IL-23, tumor
necrosis factor (TNF) and IL-6 is reduced upon incubation of dendritic cells with RvE1 [62]. In activated
T-cells lipoxin A4 lowers TNF release [63]. Protectin D1 inhibits TNF- and interferon gamma secretion
from these cells and initiates apoptosis by enhancing raft clustering [64] (Table 1). These and further
effects of the pro-resolving lipids analyzed in-vitro are summarized in Table 1. The beneficial biological
activities of these lipids in sepsis models are described in Section 2.7.
Table 1. Key effects of “specialized pro-resolving mediators” (SPM) in mononuclear and
polymorphonuclear leukocytes (PMN).
SPM Target Cell Effect Reference
Lipoxin A4
Dendritic cell IL-12 ↓ [60]
Monocyte Chemotaxis ↑ [65]
Monocyte Adhesion to laminin ↑ [65]
Macrophage Efferocytosis ↑ [66]
Macrophage Heme oxygenase 1 ↑ [14]
PMN Chemotaxis ↓ [51]
PMN Transendothelial/–epithelial migration ↓ [51]
PMN Degranulation ↓ [50]
PMN Superoxide anion ↓ [67]
PMN CCR5 ↑ [54]
T cell TNF secretion ↓ [63]
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Table 1. Cont.
SPM Target Cell Effect Reference
Maresin 1
Macrophage Phagocytosis ↑ [68]
Macrophage Killing of Porphyromonas gingivalis andAggregatibacter actinomycetemcomitans ↑ [68]
Macrophage Heme oxygenase 1 ↑ [14]
PMN Phagocytosis ↑ [68]
PMN LPS-induced resistance to apoptosis ↓ [69]
Protectin D1
Macrophage Efferocytosis ↑ [70]
Macrophage Heme oxygenase 1 ↑ [14]
PMN Transendothelial/–epithelial migration ↓ [13]
PMN CCR5 ↑ [54]
T cell TNF, IFNγ secretion ↓ [64]
T-cell Apoptosis ↑ [64]
RvE1
Dendritic cell LPS induced IL-6 ↓ [62]
Dendritic cell IL-12 ↓ [61]
Dendritic cell LPS induced IL-23 ↓ [62]
Dendritic cell LPS induced TNF ↓ [62]
Dendritic cell Migration ↓ [61]
Macrophage Efferocytosis ↑ [70]
Macrophage Heme oxygenase 1 ↑ [14]
Macrophage IL-10 ↑ [71]
Neutrophil Apoptosis ↑ [53]
PMN Transendothelial/–epithelial migration ↓ [47,72]
PMN CCR5 ↑ [54]
RvE2
Macrophage Phagocytosis ↑ [73]
Macrophage LPS-induced IL-10 ↑ [73]
PMN Chemotaxis ↓ [73]
PMN Infiltration ↓ [74]
RvD1
Macrophage M2 polarization ↑ [56]
Macrophage Efferocytosis ↑ [56]
Macrophage Autophagy ↑ [59]
Macrophage Heme oxygenase 1 ↑ [14]
Macrophage Apoptosis ↓ [58,59]
RvD2
Macrophage M2 polarization ↑ [75]
Macrophage Heme oxygenase 1 ↑ [14]
PMN Infiltration ↓ [74,76]
RvD3
Leukocyte Phagocytosis of E. coli ↑ [77]
Macrophage Efferocytosis ↑ [77,78]
Macrophage Phagocytosis ↑ [77,78]
PMN Transmigration ↓ [78]
PMN Bacterial phagocytosis ↑ [77]
PMN Intracellular reactive oxygen species ↑ [77]
PMN Platelet-PMN aggregation ↓ [77]
RvD4 PMN Infiltration ↓ [79]
CCR5, C-C chemokine receptor type 5; IFN, Interferon; IL, Interleukin; LPS, Lipopolysaccharide; Rv, Resolvin;
TNF, Tumor Necrosis Factor; PMN, polymorphonuclear leukocytes ; ↑, induced; ↓, reduced.
2.6. Receptors for Pro-Resolving Lipids
Free fatty acids and pro-resolving lipids exert their biological activities by binding to G-protein
coupled receptors and have been also described as agonists of peroxisome proliferator activated
receptors (PPARs).
The free fatty acid G-protein-coupled receptor 40 (GPR40) is activated by medium chain and long
chain fatty acids and DHA and EPA are potent agonists of this receptor. Linoleic, α-linolenic and
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arachidonic acid are further ligands of GPR40. This receptor is expressed in various cells and tissues
and is involved in metabolic and inflammatory responses of the respective agonists [80].
Unsaturated fatty acids are further ligands of the PPARs and activation of these nuclear receptors
contributes to the metabolic and anti-inflammatory activities of these lipids [81]. RvE1 suppressed
activation of NF-κB by a mechanism which partly depends on PPAR [82].
Lipoxin A4 and epi-lipoxins are agonists of the formyl peptidyl receptor 2/ALX (FPR2/ALX)
which is expressed by cells of the immune system as well as resident fibroblasts and epithelial cells.
Binding of lipoxin A4 to this receptor partly prevents its association with other agonists [83,84].
This has been for example demonstrated for the antimicrobial peptide LL-37, which is a ligand for
FPR2/ALX whose binding is blocked by lipoxin A4 [85].
Chemokine- like receptor 1 (CMKLR1) ligands are RvE1 and the adipokine chemerin [86–88].
RvE1 competes with the chemerin peptide for binding to CMKLR1, suggesting that it may partly
antagonize the biologic activities of this protein ligand. Chemerin is mainly released by adipocytes
and hepatocytes, and serum levels are elevated in inflammatory diseases [87,89,90]. Chemerin is well
described as an attractant for immune cells and may act as a pro- or anti-inflammatory protein [89].
The use of the identical receptor for a protein and a peptide ligand which both regulate immune cell
function may enable tight regulation of downstream signaling pathways.
RvE1 binding to CMKLR1 stimulates phosphorylation of Akt and ribosomal protein S6. The latter
is blocked by an extracellular signal-regulated kinase (ERK) antagonist which also inhibits RvE1
induced enhancement of zymosan A phagocytosis by human macrophages [91].
RvE1 is a partial agonist of BLT1 but does not interact with the closely related receptor BLT2 [86].
RvE1 attenuates leukotriene B4/BLT1 signaling in human leukocytes and thereby impairs activation of
NF-κB [86].
RvD1 effects on macrophages seem to be transmitted by G protein-coupled receptor 32(GPR32)
and the FPR2/ALX receptor [84,92,93].
Resolvin D2 receptor/GPR18 which is expressed by polymorphonuclear neutrophils, monocytes
and macrophages was shown to serve as RvD2 receptor [94]. RvD2 stimulates the phosphorylation of
cyclic adenosine monophosphate (cAMP) response element binding protein, STAT3 and ERK1/2 [95].
Activation of protein kinase A and STAT3 contribute to the enhanced macrophage phagocytosis of
E. coli [95].
Transient receptor potential subtype vanilloid 1 (TRPV1) and TRP ankyryn 1 (TRPA1) participate
in inflammatory pain. RvD2 is a potent inhibitor of both channels in primary sensory neurons,
RvE1 inhibits TRPV1 and RvD1 inhibits TRPA1 thus explaining the pain-relieving activities of these
lipids [96].
2.7. Specialized Pro-Resolving Mediators (SPM) in Sepsis Models
The role of pro-resolving lipids in mediating the resolution of inflammation has been tested in
murine sepsis models.
Cecal ligation and puncture in mice is a commonly used model for sepsis [97]. In a therapeutic
approach, lipoxin A4 was administered to rats 5 h after cecal ligation and puncture. Plasma IL-6,
chemokine (C-C motif) ligand 2 (CCL2), IL-10 and NF-κB activity in peritoneal macrophages were
reduced. Lipoxin A4 further attracts macrophages to the peritoneum where these cells phagocytose
bacteria and lower bacterial load [98]. Lipoxin A4 increases neutrophil phagocytosis involving the Fcγ
receptor I (CD64) and this further enhances bacterial clearance [99].
The murine ortholog to the human formyl-peptide receptor FPR2/ALX is formyl-peptide receptor
2/3 (FPR2/3) and functions as a receptor for lipoxin A4. The role of this receptor in mediating the
protective effects in sepsis was tested using the receptor agonist BML-111. This agonist ameliorated
intestinal inflammation in septic rats. The anti-inflammatory cytokine transforming growth factor-β
was induced and is supposed to protect intestinal cells from apoptotic cell death [100]. In a murine
model of non-lethal polymicrobial sepsis FPR2/3-deficient animals develop more serious disease, and
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exhibit higher cytokine levels and reduced recruitment of monocytes in peritoneal lavages. Treatment
with an FPR2/3 agonist protected wild type but not the knock-out mice from cardiac dysfunction [101].
These findings prove that pro-resolving lipids protect from organ dysfunction, a major cause of
mortality in sepsis [102]. Thus, lipoxin A4 and its receptor may become new targets in sepsis therapy.
Of note, lipoxin A4 lowers the release of the exotoxin pyocyanin by Pseudomonas aeruginosa thus
reducing its pathogenicity [99]. Thus, lipoxin A4 does not only modulate the host response, but also
affects bacterial toxicity [99].
Among the dysfunctions of sepsis, acute lung injury and the acute respiratory distress syndrome
are common complications [102]. Pneumosepsis induced in mice by inoculation with Klebsiella
pneumoniae induced lipoxin A4 and FPR2/3 expression in the lung. Treatment with receptor antagonists
and inhibition of 5- and 15-lipoxygenase in early sepsis, which is 1 h after infection, even increased
leukocyte migration to the infected tissues and survival. Receptor agonist and lipoxin A4 application
consequently worsened early infection and reduced migration of leukocytes. Later on, (24 h after
infection) lipoxin A4 improved animal survival. This study demonstrates a dual role of lipoxin A4 and
highlights the time-dependence when targeting the lipoxin A4 pathway in lung infection [103].
In an E. coli sepsis model 15-epi-lipoxin A4 injected 24 h after the insult lowered neutrophil
number in bronchoalveolar lavage by stimulating apoptosis [52].
Administration of RvD2 subsequent to cecal ligation and puncture revealed multiple beneficial
effects: (1) reduced number of live aerobic bacteria; (2) reduced number of PMN in the peritoneum;
(3) increased clearance of bacteria by phagocytes; (4) enhanced phagocytosis of E. coli by PMN;
(5) reduced pro-inflammatory cytokine levels in plasma and peritoneum; (6) lower plasma levels
of IL-10 and IL-17; (7) reduced concentrations of the pro-inflammatory lipids prostaglandin E2 and
leukotriene B4; and (8) increased survival. In a therapeutic approach RvD2 was injected 1 h after cecal
ligation and puncture and bacterial load was also reduced in the peritoneum and the blood [104].
In a mouse model of lipopolysaccharide-induced acute kidney injury, AT-RvD1 given 1 h after the
toxin did improve kidney function. Reduced infiltration of neutrophils, lower expression of adhesion
molecules and less activation of NF-κB has been reported [105].
RvD1 injected after cecal ligation and puncture increases bacterial clearance and survival. Here,
number of peritoneal neutrophils is reduced. CD3 T-lymphocytes apoptosis in thymus is even
improved [106].
Effect of RvD1 has also been tested in the D-galactosamine-sensitized mouse endotoxin shock
model. This lipid counteracted the induction of high mobility group box-1 and pro-inflammatory
cytokines. Neutrophil immigration to the peritoneum was reduced, and importantly, hepatocyte
apoptosis was also suppressed [107].
The function of RvE1 in acute lung injury was analyzed in a mouse model of aspiration pneumonia
and subsequent challenge of one lung with E. coli. Resolvin E1, when injected before the acid insult,
reduced pulmonary neutrophil infiltration and enhanced bacterial clearance. This was accompanied by
lower levels of inflammatory cytokines and chemokines and marginally improved survival rate [108].
In two murine models of acute lung injury, RvE1 suppressed pulmonary inflammation and
neutrophil counts while number of monocytes was increased. Consequently, RvE1 enhanced the
resolution of the established pulmonary inflammation [53].
All of these studies demonstrate that pro-resolving lipids resolve and timely terminate
uncontrolled inflammation. Empirical evidence for the optimal time point for intervention and
doses to be used has not been provided so far.
2.8. Systemic Levels of Pro-Resolving Lipid Species in Healthy Volunteers and Non-Septic Patients
Essential fatty acid supplementation has for long been regarded to improve health [109–111].
The essential fatty acids linoleic acid (omega-6) and α-linolenic acid (omega-3) are the precursors
for arachidonic acid or EPA and DHA, respectively. In the body, EPA and DHA are derived from
the consumption of seafood [112]. Daily consumption of EPA and DHA in adult Americans is about
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41 mg/day and 72 mg/day, respectively [113], and is rather low, especially when compared to
α-linolenic acid [112]. Further, less than 1% of α-linolenic acid may be converted to DHA. Studies in
humans indicate, that dietary intake of EPA or DHA is efficient to raise their systemic concentrations.
Such levels can´t be achieved by endogenous conversion of α-linolenic acid alone [112].
Circulating concentrations of pro-resolving lipids were measured in healthy volunteers and
patients and the effect of EPA and DHA intake was evaluated.
In a study including twelve healthy participants, seven capsules Lovaza™, corresponding to
9.7 g/day EPA and 7.9 g/day DHA (GlaxoSmithKline Pharmaceuticals, Research Triangle Park, NC,
USA) were ingested by the probands three times a day for 24.2 ± 2.3 days. RvD1 and RvE1 were
not detected in plasma while protectin was initially around 1 pg/mL and increased about three- and
four-fold after 12 and 24 days of omega-3 fatty acid intake, respectively. Maresin was approximately
4 pg/mL in plasma, and was not changed by the supplementation [114].
In a separate study, the healthy volunteers ingested two capsules Lovaza™ twice a day for
eight weeks and this did not increase SPMs including protectin. This intervention was followed
by intravenous injection of 0.6 ng/kg endotoxin, but no changes in systemic protectin and maresin
levels, measured before, 2 h and up to 72 h after endotoxin application, were observed [114]. Dietary
fish oil (460 mg EPA and 380 mg DHA as ethyl esters for four weeks) did not increase levels of
these pro-resolving lipids in the circulation [115]. Cytochrome-dependent epoxy-metabolites and
lipoxygenase-dependent monohydroxy-metabolites which are partly precursors of resolvins were
nevertheless found increased in blood and were supposed to contribute to the protective effects of fish
oil intake [114–116].
Ten healthy females selected for an omega-3 intake below 500 mg per day (intake was
102 ± 66 mg/day) obtained 2 g purified EPA in the form of free fatty acids. This lipid was diluted with
olive oil (1:1) for dietary supplementation for seven days. Olive oil was used as a placebo control and
changed several lipid species, and therefore, may have also interfered with the EPA intake associated
changes. EPA supplementation markedly elevated HEPEs including 18-HEPE which is a precursor for
RvEs. In addition, 5-, 12-, and 15-HETE were reduced by EPA. This study further detected pg/mL
concentrations of RvD1, RvD2, RvD6, maresin and protectin in plasma of humans not supplemented
with EPA [117].
In obese women, the daily intake of omega-3 fatty acids (1.8 g EPA and DHA supplemented
with 6 IU α-tocopherol) for three months increased RvD1 and RvD2 while circulating levels of
proinflammatory marker were reduced [118].
In contrast to this observation, randomised clinical trials did not identify an effect of
omega-3 supplementation on systemic levels of inflammatory cytokines and chemokines in healthy
volunteers [110].
In a further study, intake of omega-3 fatty acids and subsequent aspirin therapy was performed.
The 21 volunteers were given 1,440 mg EPA and 960 mg DHA daily for five days, thereafter 11 persons
were treated with aspirin (3 times 100 mg per day) or placebo for two days in addition to the omega-3
fatty acids. Basal levels of plasma RvE and RvD species and its precursors 18(R)/(S)-HEPE and
17(R)/(S)-hydroxydocosahexaenoic acid (HDHA) were 0.1 to 0.2 nM. 14(R)/(S)-HDHA was about
three-fold higher and maresin was not detected. Supplementation with omega-3 fatty acids increased
RvE1, 18(R)/(S)-HEPE, 17(R)/(S)-HDHA, and 14(R)/(S)-HDHA. Two days intake of aspirin did neither
alter concentrations of these lipids, nor the ratios of the enantiomeric forms [119].
In the study by Oh et al., aspirin (two times 81 mg) given prior to 1 g EPA nevertheless increased
the 18(S)- to 18(R)-HEPE ratio [46].
A combination of essential fatty acids (1 g) and aspirin (81 mg given 2 h after the lipids) induced
plasma levels of pro-resolving mediators in healthy volunteers. Phagocytic activity of blood cells was
enhanced and positively correlated with the total concentration of the pro-resolving lipids [120]. This
study not only demonstrated that pro-resolving lipids are endogenously formed, but importantly
proved their biologic activity [120].
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The studies described above used different doses and duration of omega-3 fatty acid intake. Lipids
were partly supplemented with α-tocopherol (Lovaza™ is supplemented with 6 IU of α-tocopherol
per capsule [121]) or olive oil. Aspirin was either given before or after omega-3 fatty acids and doses
varied. Therefore, it is impossible to compare the different studies.
It seems that very high doses of omega-3 fatty acids do not cause a more prominent increase of
SPMs and its precursors compared to lower doses. However, sensitivity of the methods to measure
these lipid species may vary and partly explain why these lipids were detected in some but not other
analyses. Further studies have to evaluate time- and dose-response relationships. Supplementation
with α-tocopherol may suppress 5-LOX activity in immune cells and thus may interfere with the
formation of the pro-resolving lipid species [122,123].
Beneficial effects of EPA intake have been further analyzed in patients undergoing hepatobiliary
resections. Twenty patients received oral supplementation (1000 kcal/day) with omega-3 fatty acids,
arginine, and nucleotides (oral IMPACT®) (Nestle Health Science Co., Ltd., Kobe, Japan) while regular
food was restricted to 1000 kcal/day for five days before the surgery. Twenty patients obtaining
regular food (2000 kcal/day) were used as controls. In the supplemented patients, systemic EPA
levels increased and rapidly normalized when oral IMPACT uptake was stopped. EPA intake had no
influence on plasma RvE1-levels which were about 1 µg/mL, and much higher when compared to
other studies where levels are in the pg/mL-range [124,125]. Of note, levels of RvE1 were induced in
both groups immediately after the surgery. Patients with omega-3 fatty acid intake had a more distinct
RvE1 increase and a lesser postoperative raise of IL-6. Further, postoperative complications were less
severe in patients with “immunonutrition” [125].
Effects of short-term oral supplementation with omega-3 fatty acids (4.4 g fish oil, four weeks)
have also been studied in patients with peripheral artery disease. In the 40 patients enrolled, endothelial
function (measured by brachial artery flow-mediated vasodilation) and levels of pro-inflammatory
cytokines (measured in serum) were similar to the 40 controls. Lipoxygenase products 4-HDHA,
5-HEPE, 12-HEPE, and 15-HEPE and cytochrome P450 product 18-HEPE were increased by fish oil
supplementation. RvE1 could not be measured and levels were below the detection limit. This dietary
intervention was effective and caused a prominent decrease in triglycerides and a modest increase in
high-density lipoprotein levels [109].
2.9. Pro-Resolving Lipid Species in Sepsis Patients
Sepsis is defined as "life-threatening organ dysfunction due to a dysregulated host response to
infection" [126], and is a major cause of mortality and morbidity [126,127]. Acute respiratory distress
syndrome (ARDS) is a relatively common and serious complication of pulmonary and non-pulmonary
sepsis causing respiratory dysfunction [128].
Clinical trials so far failed to improve all-cause mortality in sepsis patients for several reasons [127].
One major challenge is the heterogeneity of the patients enrolled. Further, sepsis pathophysiology is
not well-understood [127]. Analysis of pro-resolving lipids in these patients may identify novel targets
for therapy and give further insights into pathways contributing to disease progression.
In 22 sepsis patients of whom nine were non-survivors, serum lipids were measured within
48 h of admission, and three and seven days later. In non-survivors, increases in prostaglandin
F2α, leukotriene B4, RvE1, RvD5 and protectin D1 levels were found. Importantly, protectin D1
concentrations were related to the development of respiratory failure [124]. This study identified
increased levels of inflammatory and pro-resolving lipids in sepsis patients which do not survive [124].
This illustrates that pro- and anti-inflammatory pathways are excessively activated in sepsis, and thus,
inflammation prevails.
In 66 sepsis patients of whom 39 survived within the 28 days of admission to the intensive care
unit, lipoxin A4 was significantly reduced compared to controls, but levels of this lipid were not
associated with death [129].
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Separate studies analyzed effects of supplementation with fish oil in sepsis patients. Results
of these investigations are nicely summarized in recent review articles [130,131]. In summary,
the parenteral administration of fish oil emulsions is not recommended in critically ill patients.
Although mortality was reduced in some cohorts, this was not confirmed in others [130,131]. Different
results may be explained by the heterogeneous study designs regarding dose and composition of fatty
acids, varying disease states and comorbidities of the patients enrolled.
2.10. Aspirin in Sepsis
Aspirin is an anti-inflammatory drug and by acetylating COX2, it induces a shift from the
synthesis of pro-inflammatory to pro-resolving lipid mediators namely aspirin-triggered lipoxins and
aspirin-triggered resolvins [13,132] (Figure 4).
In murine models of sepsis and acute respiratory syndrome aspirin proved to effectively increase
survival [128]. A study published in 1983 already reported beneficial effects of aspirin in a rat model
of sepsis [133]. Salmonella enteritidis endotoxin was applied to induce endotoxin shock in Long-Evans
rats. Aspirin in doses of 3.75, 15, and 30 mg/kg administered 30 minutes prior to the toxin improved
survival. Levels of arachidonic acid-derived lipid mediators such as thromboxanes and prostaglandins
were reduced as expected [133].
Pre-hospital aspirin intake and outcome in sepsis patients has been evaluated in several
observational studies. In a study including 1,149 critically ill patients, 32% developed acute respiratory
distress syndrome within the first four days. The 25% of the patients with pre-clinical aspirin therapy
had a decreased risk of developing this complication. This association was found in the whole study
group and the subgroup of patients with sepsis. Mortality tended to be lower in patients taking aspirin
before hospitalization [134].
In a group of 5,523 patients with systemic inflammatory response syndrome or sepsis, 2,082
patients were given aspirin within 24 h after diagnosis. Mortality was significantly reduced in the
latter group [135].
In a separate study including 1,005 patients with community-onset pneumonia intake of
100 mg/day of aspirin was associated with a lower mortality rate within 30 days [136].
A multi-center study encompassing 3,855 patients did not identify a significant association
between pre-hospital aspirin use and progress to acute respiratory distress syndrome [137].
A prospective observational study with 972 patients published recently shows that pre-hospital
antiplatelet therapy, which was aspirin for 95.5% of the patients, was neither associated with the
development of organ failure or shock or 90 days mortality up to 90 days after admission, in either
unmatched or propensity-matched analysis [138].
Present findings on aspirin therapy do not permit any final conclusions on potential beneficial
outcomes in sepsis. Patients with pre-hospital aspirin intake may suffer from type 2 diabetes,
hypertension, coronary artery disease, congestive heart failure, chronic kidney disease, cerebrovascular
disease and peripheral vascular disease, and this may increase mortality [134]. In addition, doses of
aspirin varied further complicating the interpretation of these results.
There are several planned/ongoing trials to evaluate a possible protective function of aspirin in
patients with sepsis and acute respiratory distress syndrome [128].
2.11. Carbon Monoxide in Sepsis Models
Aspirin was shown to upregulate HO-1 [139], an enzyme exerting anti-oxidative and
anti-inflammatory activities in various diseases by catalyzing the production of carbon monoxide [27].
Consequently, the roles of HO-1 and carbon monoxide were investigated in murine sepsis. Higher
mortality and hepatic necrosis in HO-1-deficient mice injected with endotoxin suggest a protective
function of this enzyme [140]. By using agents trapping or enhancing carbon monoxide levels,
hepatoprotective effects of this gas were reported in perfused livers of endotoxemic rats [15].
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Carbon monoxide released from tricarbonyldichlororuthenium-(II)-dimers attenuated hepatic
accumulation of PMN, expression of the Intercellular Adhesion Molecule 1 (ICAM-1) and activation of
NF-κB in murine polymicrobial sepsis [141]. In endotoxin-activated human umbilical vein endothelial
cells the production of reactive oxygen species, nitric oxide, activation of NF-κB, induction of inducible
NO synthase and ICAM-1, and consequently PMN adhesion were reduced [141].
Inhalation of carbon monoxide (250 ppm) increased the survival of mice after cecal ligation and
puncture. Of note, this effect was observed when carbon monoxide inhalation was done before and
after the intervention. The bacterial number in blood and several organs and levels of circulating
inflammatory cytokines were reduced. Carbon monoxide enhanced autophagy and phagocytosis
which contributes to its protective effects, and was confirmed in animals deficient in the autophagic
protein Beclin-1 [142].
A ruthenium-based water-soluble carrier (tricarbonylchoro(glycinato)ruthenium (II)) functions
as a carbon monoxide releasing molecule and improved survival in a murine sepsis model. Cardiac
mitochondrial function and mitochondrial biogenesis were restored demonstrating that carbon
monoxide protects from organ dysfunction in sepsis [143].
Carbon monoxide inhalation 2 h prior to the initiation of peritonitis lowered the number of
infiltrating PMN by about 40%. Monocyte numbers were unchanged, but their capacity to eliminate
microbial particles and dead PMN was enhanced [14]. In treated mice, inflammation resolved about
two-times faster compared to non-exposed animals. Lipid mediators derived from arachidonic acid,
leukotriene B4 and prostaglandin E2, were reduced during early inflammation and pro-resolving lipids
originating from EPA and DHA, namely RvD1, RvE2 and maresin, were elevated [14].
Carbon monoxide released from carbon monoxide-releasing molecule 2 (CORM-2) increased
survival of lipopolysaccharide injected mice. CORM-2 induced the internalization of formyl
peptide receptor 1 and this contributes to reduced neutrophil infiltration in liver and lung [144].
Carbon monoxide induces lipoxygenases, thereby stimulating SPM production and inhibits P450-like
enzymes involved in SPM degradation [14]. Pro-resolving lipids, furthermore, induce HO-1 levels in
macrophages demonstrating mutual amplification of these two pro-resolving pathways (Figure 2) [14].
In a murine model of acute lung injury carbon monoxide reduced PMN lung infiltration as well as
leukotriene and thromboxane levels. In non-human primates infected with Streptococcus pneumoniae
carbon monoxide inhalation lowered urinary cysteinyl leukotrienes indicating protection from lung
injury in these animals [145].
Mesenchymal stromal cell-based therapies are innovative approaches to cure sepsis. Treatment of
these cells with carbon monoxide prior to delivery via the tail vein of septic mice, increased animal
survival. Bacterial load and organ damage improved. Simultaneous exposure of mesenchymal
stromal cells to carbon monoxide and DHA increased the synthesis of D-series resolvins. Cells lacking
lipoxygenases, which are essential for resolvin synthesis from DHA, did not exert favorable effects
upon carbon monoxide preconditioning [146]. This experiment proves that production of resolvins is a
downstream effect of carbon monoxide exposure mediating the pro-resolving activities of this gas.
2.12. Carbon Monoxide in Clinical Studies
Endogenous carbon monoxide is mostly a product of hemoglobin turnover, but is also released
when other hemoproteins such as cytochrome P450 proteins are catabolized. Carbon monoxide
associates with hemoglobin to form carboxyhemoglobin whose basal concentrations are 0.1%–1% [147].
Induction of HO-1 in inflammation may contribute to increased levels of carboxyhemoglobin in blood
and carbon monoxide in exhaled air.
Patients with lower respiratory tract infection indeed had higher carbon monoxide in their breath
(nearly two-fold higher compared to controls) and levels declined in those patients recovering from
disease after antibiotic treatment [148]. Plasma carbon monoxide in seven term newborn infants with
sepsis was significantly increased when compared to 30 healthy neonates [149].
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Arterial blood carbon monoxide and HO-1 protein levels in monocytes were induced in 36
patients with severe sepsis or septic shock compared to 21 patients without sepsis. Importantly, HO-1
expression in monocytes and arterial carbon monoxide were positively related to survival [150].
A further study reported that exhaled carbon monoxide was 1.7-fold higher in critically ill patients
compared to controls. Interestingly, levels correlated with carboxyhemoglobin [151]. In mechanically
ventilated patients with severe sepsis or septic shock, exhaled carbon monoxide was nearly three-fold
higher compared to controls (which were five patients with varying diagnoses) and declined during
therapy [152]. Of note, high amount of carbon monoxide in exhaled air on the first day of treatment
was associated with better survival [152]. These findings suggest an association of endogenous carbon
monoxide production and recovery from disease in severely ill patients.
To support this assumption, the effect of carbon monoxide inhalation was tested in humans
injected with endotoxin. Healthy volunteers were exposed to 500 ppm carbon monoxide for 1 h or
normal air as control prior to the injection of endotoxin. Carboxyhemoglobin levels and inflammatory
cytokines in plasma were similarly increased in both groups [153]. The results of this study do not
argue for carbon monoxide therapy in sepsis. Translation of this approach to patients requires empirical
data on dose-response of carbon monoxide and its pro-resolving effects. Beneficial effects of carbon
monoxide inhalation have been reported in different patient cohorts, and there are ongoing studies to
test the suitability of this gas for the treatment of sepsis patients [30].
3. Conclusions
Sepsis is a systemic inflammatory disease with a high mortality risk. Despite encouraging
results in preclinical models, all of the putative therapeutic agents tested so far failed in clinical
trials. Excessive uncontrolled inflammation and improper immune response are both characteristic
features of sepsis that complicate identification of suitable drug targets. Dampening inflammation
may delay its resolution because of an inappropriate induction of anti-inflammatory and pro-resolving
pathways. Carbon monoxide and various pro-resolving lipids accelerate resolution of inflammation
and improve survival in animal studies. Thus, current preclinical studies revealed encouraging results
towards their therapeutic aspects in sepsis. Indeed, the rodent models used to analyze the therapeutic
potential of these mediators were similar/identical to those employed in the previous studies where
protective effects of diverse molecules could not be reproduced in sepsis patients. However, these
new mediators do not simply dampen inflammation but contribute to its timely resolution. Therefore,
the potentially beneficial effects of these mediators in human sepsis have to be evaluated in clinical
trials. This requires empirical evidence regarding optimal composition and doses, time points for
application and bioavailability of the agents.
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